APIMEDS PHARMACEUTICALS US I (APUS) Stock Price & Overview
NYSEARCA:APUS • US03771D1028
Current stock price
The current stock price of APUS is 1.64 USD. Today APUS is up by 1.23%. In the past month the price increased by 33.33%.
APUS Key Statistics
- Market Cap
- 20.631M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.12
- Dividend Yield
- N/A
APUS Stock Performance
APUS Stock Chart
APUS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to APUS.
APUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APUS. APUS has a great financial health rating, but its profitability evaluates not so good.
APUS Earnings
APUS Forecast & Estimates
APUS Groups
Sector & Classification
APUS Financial Highlights
Over the last trailing twelve months APUS reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS decreased by -78.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.18% | ||
| ROE | -14.27% | ||
| Debt/Equity | 0 |
APUS Ownership
APUS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.92 | 391.561B | ||
| AMGN | AMGEN INC | 16.05 | 197.434B | ||
| GILD | GILEAD SCIENCES INC | 16.43 | 180.267B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.04 | 118.403B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.19 | 80.02B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.74 | 42.294B | ||
| INSM | INSMED INC | N/A | 31.168B | ||
| NTRA | NATERA INC | N/A | 28.017B | ||
| BIIB | BIOGEN INC | 11.4 | 26.895B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.89 | 23.418B | ||
| MRNA | MODERNA INC | N/A | 21.054B | ||
| EXAS | EXACT SCIENCES CORP | 341.66 | 19.824B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.619B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APUS
Company Profile
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
Company Info
IPO: 2025-05-09
APIMEDS PHARMACEUTICALS US I
100 Matawan Road, Suite 325
Matawan NEW JERSEY US
Employees: 2
Phone: 18482015010
APIMEDS PHARMACEUTICALS US I / APUS FAQ
What does APIMEDS PHARMACEUTICALS US I do?
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
What is the stock price of APIMEDS PHARMACEUTICALS US I today?
The current stock price of APUS is 1.64 USD. The price increased by 1.23% in the last trading session.
Does APUS stock pay dividends?
APUS does not pay a dividend.
What is the ChartMill technical and fundamental rating of APUS stock?
APUS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the ownership details for APUS stock?
You can find the ownership structure of APIMEDS PHARMACEUTICALS US I (APUS) on the Ownership tab.